Martin Haluzík

28PUBLICATIONS
86CO-AUTHORS
Metabolic medicineApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)PharmacogenomicsCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|Jan 20, 2026
Untargeted Metabolomics Identifies N-Lactoyl-Amino Acids as Dose-Responsive Plasma Biomarkers of Metformin Adherence in Type 2 Diabetes.

Tomas Cajka, Jiri Hricko, Lucie Rudl Kulhava

|Dec 15, 2025
Insulin therapy DE-intensificAtion with iGlarLixi: A phase 4, open-label, parallel-group randomised controlled trial.

Peter Novodvorský, Lenka Thieme, Ivana Laňková

|Oct 10, 2025
Partial non-adherence to antidiabetic therapy undermines diabetes management and correlates with treatment complexity: A cross-sectional study using blood plasma analysis.

Vojtěch Škop, Ivana Laňková, Simona Antalová

|Jul 28, 2025
Practical limitations of complex insulin therapies in type 2 diabetes: Focus on therapy simplification using fixed-ratio combinations of basal insulin and a glucagon-like peptide-1 receptor agonist.

Luděk Horváth, Peter Novodvorský, Martin Haluzík

|May 07, 2025
Role of ANT2 in mitochondrial function and cancer cell survival: a target for therapeutic intervention.

Klara Bohacova, Zuzana Nahacka, Jana Dudova

|Mar 18, 2025
Efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes: The Soli-SWITCH study.

Martin Haluzík, Katarzyna Cypryk, Agustina Alvarez

Pageof 5

Frequent Collaborators

4 joint publications

Julio Rosenstock

3 joint publications

Vanita R Aroda

3 joint publications

Tomas Cajka

3 joint publications

Sona Stemberkova Hubackova